with MMF (from sFr. 5906 to 9231 per patient for the first 6 months). Background. Several multinational controlled clinical trials have shown that triple therapy immunosuppres-Conclusions. The change from AZA to MMF resulted in a significant reduction in early rejection episodes, sive regimens which include mycophenolate mofetil (MMF ), cyclosporin A (CSA) and steroids (S ) are resulting in fewer diagnostic procedures and rehospitalizations. The optimal long-term regimen in terms of superior compared with conventional regimens which include azathioprine (AZA), CSA and S, mainly patient and pharmacoeconomic benefits remains to be defined. because MMF reduces the rate of acute rejection episodes in the first 6 months after kidney transplantation. Post-marketing studies are useful to evaluate the Key words: mycophenolate mofetil; pharmacoecongeneral applicability and costs of MMF-based omy; rejection; renal transplantation immunosuppressive regimens. shown that the MMF regimen reduced the rate of patients transplanted immediately prior to the change biopsy-proven acute rejection episodes from 40.8% in in regimen (AZA group).
lished controlled clinical trials, we have changed Introduction the standard triple therapy immunosuppressive protocol (AZA+CSA+S) to an MMF-based regimen Several large randomized controlled clinical trials have (MMF+CSA+S ) at our centre. To analyse the impact demonstrated that the novel immunosuppressive drug of this change in regimen, we have monitored 6-month mycophenolate mofetil (MMF, CellCeptB) significpatient and graft survival, rejection rate, serum creatinantly reduces the rate of early acute rejection episodes ine and CSA levels, as well as the costs of the immunoafter renal allograft transplantation when compared suppressive and anti-rejection treatments, in 40 with azathioprine (AZA) or placebo [1] [2] [3] [4] . The pooled consecutive renal transplant recipients (MMF group) 1-year efficacy analysis of three clinical studies has and have compared the data with 40 consecutive shown that the MMF regimen reduced the rate of patients transplanted immediately prior to the change biopsy-proven acute rejection episodes from 40.8% in in regimen (AZA group).
the AZA or placebo groups to 19.8% in the patients Results. Recipient and donor characteristics were simtreated with 2 g of MMF per day [5] . Side effects as ilar in the AZA and MMF groups. Patient survival well as infectious and neoplastic complications were (37/40; 92.5% in the AZA group vs 38/40; 95% in the similar with MMF. MMF group), graft survival (36/40 vs 36/40; both Despite the excellent results on the rate of acute 90%) and serum creatinine (137±56 vs 139±44 rejection episodes, the 1-year analysis has revealed that mmol/l ) after 6 months were not significantly different.
patient survival was not better with MMF (96%) However, the rate of acute rejection episodes (defined compared with the placebo/AZA regimens (95.3%). as a rise in creatinine without other obvious cause
The graft survival with MMF (90.4%) was also similar and treated at least with pulse steroids) was signifiwhen compared with placebo or AZA (87.6%) [5] . cantly reduced with MMF from 60 to 20% (P= Whether long-term benefits could result with the MMF 0.0005). The resulting cost for rejection treatment was regimen has not been investigated yet. The 3-year lowered 8-fold (from sFr. 2113 to 259 averaged per results suggest that a trend towards better graft survival patient) and the number of transplant biopsies was can be obtained with MMF [6, 7] . lowered >3-fold in the MMF group. The cost for the Aside from the documented advantage for the immunosuppressive therapy was increased 1.5-fold patient treated with MMF, another important issue is the cost of immunosuppression. Analyses at 1 year 
Results

Subjects and methods
Comparison of groups Study design
A total of 80 patients were analysed in this study, including 40 historical control patients (AZA group)
We compared patient and graft survival, rejection rates, serum creatinine and cost of immunosuppression in 40 and 40 patients treated with a regimen containing consecutive kidney transplant patients treated with MMF MMF (MMF group). Table 1 demonstrates the basewith a historical control group of 40 renal transplant patients line characteristics of the two groups. Both groups treated with AZA. The standard immunosuppression (AZA were similar with respect to age, sex, height, weight, group) was a triple therapy regimen which included the cause of end-stage renal disease, presence or absence cyclosporin A (CSA) microemulsion Sandimmune NeoralB of panel-reactive anti-HLA antibodies (number of sens-(initial dose 8 mg/kg, then tapering to achieve CSA levels itized patients) and previous mode of dialysis. The between 150 and 250 ng/ml ), prednisone (initial dose number of patients who were retransplants was higher 1 mg/kg/day; then tapering to a dose of 10 mg/day within 6 in the AZA group (5 vs 1; P=0.2).
months after transplantation) and AZA (1-1.5 mg/kg/day). Sandimmune was given intravenously at 3 mg/kg/day for the
The donor characteristics were also quite similar first 24 h. Sensitized patients, retransplants, patients with ( Table 2 ). More recipients in the MMF group disdelayed graft function or patients receiving a transplant with played delayed graft function (25% vs 12.5%; P=0.25) donor age >65 received a 7-day course of Anti-Thymocyte despite comparable cold ischaemia times of the grafts, Globulin (ATG) (Fresenius, 3 mg/kg/day i.v.) for induction reflecting perhaps the slightly higher age of the donors treatment with delayed introduction of CSA. MMF was used in the MMF group. The number of HLA-A, -B and at a dose of 2×1 g/day instead of AZA in the MMF group. -DR mismatches was also not different between donors and recipients, and the cytomegalovirus (CMV ) constellations between donor and recipients were also Outcome measurements similar.
Donor and recipient characteristics were compared and examined for statistically significant differences. Patient and Efficacy graft survival rates were then determined after 6 months in Table 3 shows that the 6-month patient survival rates both groups. Episodes of acute rejection-defined as a rise in serum creatinine not due to obstruction, hypovolaemia, were similar in both treatment groups (95% in the cyclosporin toxicity or any other obvious cause and treated MMF group vs 92.5% in the AZA group). Likewise, at least with pulse steroids (500-1000 mg for 3-5 days)-the graft survival rates were not different (90% in both were recorded in both groups and the results of any biopsies groups). The causes of death and graft failure are also were also checked. Serum creatinine, immunosuppression reported in Table 3 . Due to the low number of events, and cyclosporin levels were also recorded at 3 and 6 months a significant difference cannot be excluded.
and compared.
The systematic use of MMF instead of AZA reduced We also analysed the cost of the baseline immunosuppres-the incidence of clinically diagnosed acute rejection epission and the costs of induction and rejection treatments in odes in the first 6 months after transplantation from both groups. The cost of the baseline immunosuppression 60% to 20% (P=0.0005). Table 4 demonstrates that was estimated in Swiss Francs based on average doses used of Sandimmune NeoralB (300 mg/day), AZA (75 mg/day), steroid-sensitive episodes were the most frequent type of MMF (2 g/day) and prednisone (20 mg/day) in the first 6 acute rejection, and their number was markedly reduced months after transplantation. Costs of the induction treat-in the MMF group. The number of ATG or OKT3 ments with ATG (7×200 mg), and costs for rejection treat-treatments for steroid-resistant rejection was also ments were calculated based on average treatments with reduced in the MMF group (due in part also to the pulse steroids (5×1 g i.v. methylprednisolone), ATG recent availability in 1997 of FK506 to treat steroidFresenius (7×200 mg) or OKT3 (7×5 mg). In addition, we resistant rejection episodes). Table 4 also shows that the recorded the number of transplant biopsies (reflecting the mean time to rejection was similar in both groups. diagnostic activity due to presumed rejection) and examined Table 5 demonstrates that significantly fewer diathe number of prolonged hospitalizations and rehospitalizagnostic transplant biopsies were needed in the MMF tions for treatment of rejection (reflecting supplemental hospital costs due to rejection). group compared with the AZA group (8 vs 27). Baseline donor characteristics were recorded and analysed for differences. Averaged data represent mean±SD. The donor age and cold ischaemia time ranges are indicated in parentheses. No statistically significant differences were detected between the two groups. Patient and graft survival rates and the causes of death and graft failure are reported for both groups.
Advantages of mycophenolate mofetil in renal transplantation 397 Table 7 indicates the cost of the two regimens averaged per patient for the 6-month period. Whereas the
The number of patients with none, 1, 2 and 3 or more rejection episodes in the first 6 months after transplantation is reported. immunosuppression therapy was 1.8-fold more expensFurthermore, the number of treatments with methylprednisolone ive with MMF, 8-fold greater costs arose from the bolus, ATG or ATGAM, FK506 ('rescue') or OKT3 is indicated, treatment of the more frequent rejection episodes in demonstrating that MMF markedly reduces the incidence of acute the AZA group. Due to the higher number of induction expenses resulted from ATG induction treatments in the MMF group. The total estimated costs for immunosuppressive drugs was 24% higher in the Table 5 . Diagnostic biopsies and rejection type (Banff ) patients in the MMF group in the first 6 months.
Important additional savings could be documented AZA MMF in the MMF group, although the amount of these costs could not be estimated. For example, 3-fold less tests and radiological procedures such as transplant ultrasound examinations in the MMF group. In addi-
The number of diagnostic biopsies in the first 6 months after tion, in the MMF group, there were also fewer protransplantation and the Banff grading is reported. Significantly fewer biopsies were performed in the MMF group.
longed hospitalizations and rehospitalizations for the treatment of steroid-resistant rejection episodes, which generally require central line placement and i.v. ATG Classification of these biopsies according to the Banff treatment (data not shown). scheme [10] revealed that the histopathological lesions were similar in both groups, with more than half of the biopsies showing a normal histology or non-specific Discussion changes.
The serum creatinine values at 6 months were also This study reports on the successful use of MMF not different in the two groups (137±56 mmol/l in the instead of AZA after renal allograft transplantation at AZA group vs 139±44 in the MMF group). Table 6 a single centre. The change from AZA to MMF shows that the average daily doses of prednisone and decreased the 6-month rejection rate 3-fold from 60 to cyclosporin did not differ at any time between the two 20%. Our data are in agreement with the previously groups, nor was there a significant difference in the reported international trials [1-4] and demonstrate cyclosporin levels. More patients were treated with that an individual centre can successfully reduce the ATG induction in the MMF group (57.5% vs 40%; rate of acute rejection episodes in renal transplant P=0.18). This could have influenced the rejection patients when changing from an AZA-containing to rate slightly.
an MMF-containing triple therapy regimen. The additional benefits of this treatment strategy are a lower Side effects requirement for diagnostic procedures and fewer rehospitalizations for treatment of steroid-resistant rejection Treatment failures were low and comparable in both groups. The number of patients with functioning episodes.
Our study is the first to document enhanced effectgraft at 6 months on the initial triple regimen (MMF+prednisone+CSA) was 32/36, compared with iveness of MMF compared with AZA in Sandimmune NeoralB (CSA microemulsion)-treated patients; the 35/36 with the AZA+prednisone+CSA regimen.
During the 6-month observation period, no serious previously published studies were all performed with The initial regimen, the use of ATG induction therapy with ATG Fresenius and the mean±SD dosages of cyclosporin, prednisone, azathioprine and mycophenolate mofetil are reported at 3 and 6 months for both groups. 
